Azitra, Inc.

AMEX: AZTR · Healthcare · Biotechnology

PublicHQ Branford, CTCIK 0001701478Reports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

29D

FH 33DQ 33GM 11SS 24

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$11.0M

Employees

Market cap

$1.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$11.0M-$11.0M2025

Operating income-$11.0M-$11.0M2025

Total assets$5.0M$5.0M2025

Liabilities$1.2M$1.2M2025

Equity$3.8M$3.8M2025

Revenue trend

FY2023 – FY2025 · USD

$284.0k

FY23

$686.0k

FY23

$7.5k

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Azitra, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Procyon Corporation——CBD of Denver, Inc.35D Sirona Biochem Corp.——Kelyniam Global, Inc.——

Key facts

CEOFrancisco D. Salva

SectorHealthcare

IndustryBiotechnology

HeadquartersBranford, CT

ExchangeAMEX: AZTR

Employees12

IPO date2023-06-20

Latest filings

8-K2026-06-17 8-K2026-06-16 8-K2026-06-04 8-K2026-05-27 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-05-08 8-K2026-03-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.